Renal clearance is usually predicted via empirical approaches including quantitative
structure activity relationship and allometric scaling. Recently, mechanistic prediction …

Abstract Background and Objectives The kidney is a major drug-eliminating organ. Renal
impairment or concomitant use of transporter inhibitors may decrease active secretion and …

Radioimmunoassayed serum concentration and urinary excretion data for digoxin from
azotemic patients were characterized using a 2‐compartment open model. Urinary excretion …

Unmanageable severe adverse events caused by drug‐drug interactions (DDIs), leading to
market withdrawals or restrictions in the clinical usage, are increasingly avoided with the …

Elevated serum creatinine (SCr) caused by the inhibition of renal transporter (s) may be
misinterpreted as kidney injury. The interpretation is more complicated in patients with …

Disease states such as liver cirrhosis and chronic kidney disease can lead to altered
pharmacokinetics (PK) of drugs by influencing drug absorption, blood flow to organs, plasma …

Physiologically based pharmacokinetic (PBPK) modeling and classical population
pharmacokinetic (PK) model‐based simulations are increasingly used to answer various …

The predictive performance of physiologically‐based pharmacokinetics (PBPK) models for
pharmacokinetics (PK) in renal impairment (RI) and hepatic impairment (HI) populations was …

Quantitative prediction of the impact of chronic kidney disease (CKD) on drug disposition
has become important for the optimal design of clinical studies in patients. In this study …

A P-glycoprotein (P-gp) IC50 working group was established with 23 participating
pharmaceutical and contract research laboratories and one academic institution to assess …